SlowBull
The Business Brief FRIDAY, 28 AUGUST 2026
← All stories
Markets

AstraZeneca, Ionis data spark debate about RNA drugs’ impact on deadly heart disease

1 source ·1 article ·2h ago

Results published in NEJM raised questions about the benefits “silencer” medications provide on top of standard therapies for TTR cardiomyopathy and amplified investor pressure on Alnylam.

Covered by 1 outlet

Biopharmadive 1

All coverage · 1 article

BioPharma Dive ·2h ago

AstraZeneca, Ionis data spark debate about RNA drugs’ impact on deadly heart disease

Results published in NEJM raised questions about the benefits “silencer” medications provide on top of standard therapies for TTR cardiomyopathy and amplified investor pressure on Alnylam.